View in EDS PDF Full Text

Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma.

Saved in:
Bibliographic Details
Title: Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma.
Authors: Durgin JS; Glioblastoma Translational Center of Excellence, The Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, United States.; Department of Pathology & Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States., Henderson F Jr; Department of Neurosurgery, Medical University of South Carolina, Charleston, SC, United States., Nasrallah MP; Glioblastoma Translational Center of Excellence, The Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.; Department of Pathology & Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States., Mohan S; Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States., Wang S; Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States., Lacey SF; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, United States., Melenhorst JJ; Glioblastoma Translational Center of Excellence, The Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, United States.; Department of Pathology & Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States., Desai AS; Glioblastoma Translational Center of Excellence, The Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.; Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States., Lee JYK; Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States., Maus MV; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, United States., June CH; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, United States.; Department of Pathology & Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States., Brem S; Glioblastoma Translational Center of Excellence, The Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.; Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States., O'Connor RS; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, United States.; Department of Pathology & Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States., Binder Z; Glioblastoma Translational Center of Excellence, The Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.; Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States., O'Rourke DM; Glioblastoma Translational Center of Excellence, The Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.; Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.
Source: Frontiers in oncology [Front Oncol] 2021 May 07; Vol. 11, pp. 669071. Date of Electronic Publication: 2021 May 07 (Print Publication: 2021).
Publication Type: Case Reports; Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34026647
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Durgin+JS%22">Durgin JS</searchLink>; Glioblastoma Translational Center of Excellence, The Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, United States.; Department of Pathology & Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22Henderson+F+Jr%22">Henderson F Jr</searchLink>; Department of Neurosurgery, Medical University of South Carolina, Charleston, SC, United States.<br /><searchLink fieldCode="AU" term="%22Nasrallah+MP%22">Nasrallah MP</searchLink>; Glioblastoma Translational Center of Excellence, The Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.; Department of Pathology & Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22Mohan+S%22">Mohan S</searchLink>; Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22Wang+S%22">Wang S</searchLink>; Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22Lacey+SF%22">Lacey SF</searchLink>; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22Melenhorst+JJ%22">Melenhorst JJ</searchLink>; Glioblastoma Translational Center of Excellence, The Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, United States.; Department of Pathology & Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22Desai+AS%22">Desai AS</searchLink>; Glioblastoma Translational Center of Excellence, The Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.; Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22Lee+JYK%22">Lee JYK</searchLink>; Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22Maus+MV%22">Maus MV</searchLink>; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, United States.<br /><searchLink fieldCode="AU" term="%22June+CH%22">June CH</searchLink>; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, United States.; Department of Pathology & Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22Brem+S%22">Brem S</searchLink>; Glioblastoma Translational Center of Excellence, The Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.; Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22O'Connor+RS%22">O'Connor RS</searchLink>; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, United States.; Department of Pathology & Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22Binder+Z%22">Binder Z</searchLink>; Glioblastoma Translational Center of Excellence, The Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.; Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22O'Rourke+DM%22">O'Rourke DM</searchLink>; Glioblastoma Translational Center of Excellence, The Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.; Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2021 May 07; Vol. 11, pp. 669071. <i>Date of Electronic Publication: </i>2021 May 07 (<i>Print Publication: </i>2021).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Case Reports; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34026647
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2021.669071
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 669071
    Titles:
      – TitleFull: Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Durgin JS
      – PersonEntity:
          Name:
            NameFull: Henderson F Jr
      – PersonEntity:
          Name:
            NameFull: Nasrallah MP
      – PersonEntity:
          Name:
            NameFull: Mohan S
      – PersonEntity:
          Name:
            NameFull: Wang S
      – PersonEntity:
          Name:
            NameFull: Lacey SF
      – PersonEntity:
          Name:
            NameFull: Melenhorst JJ
      – PersonEntity:
          Name:
            NameFull: Desai AS
      – PersonEntity:
          Name:
            NameFull: Lee JYK
      – PersonEntity:
          Name:
            NameFull: Maus MV
      – PersonEntity:
          Name:
            NameFull: June CH
      – PersonEntity:
          Name:
            NameFull: Brem S
      – PersonEntity:
          Name:
            NameFull: O'Connor RS
      – PersonEntity:
          Name:
            NameFull: Binder Z
      – PersonEntity:
          Name:
            NameFull: O'Rourke DM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 07
              M: 05
              Text: 2021 May 07
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 11
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1